Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

被引：0
作者：
Juanjuan Zhao
Quan Ren
Xinyuan Liu
Xiangqian Guo
Yongping Song
机构：
[1] The First Affiliated Hospital of Zhengzhou University,Department of Hematology
[2] Henan University,Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences
来源：
Journal of Hematology & Oncology | / 16卷
关键词：
Multiple myeloma; Bispecific antibody; BCMA; GPRC5D; FcRH5;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.
引用
收藏
相关论文
共 178 条
[1]  
Moreau P(2023)Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) J Clin Oncol 41 8011-8011
[2]  
Garfall AL(2023)Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies J Clin Oncol 41 8049-8049
[3]  
Bhutani M(2023)MajesTEC-9: a randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma J Clin Oncol 41 8067-8067
[4]  
Oriol A(2023)Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study J Clin Oncol 41 8039-8039
[5]  
Nooka AK(2023)MagnetisMM-6: an open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) J Clin Oncol 41 TPS065-TPS8065
[6]  
Martin TG(2023)MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma J Clin Oncol 41 TPS8066-TPS8066
[7]  
Rosiñol L(2023)LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma J Clin Oncol 41 8006-8006
[8]  
Mateos M-V(2023)Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma J Clin Oncol 41 8038-8038
[9]  
Bahlis NJ(2023)Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting J Hematol Oncol 16 60-8036
[10]  
Popat R(2023)Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM) J Clin Oncol 41 8036-8002
12345678910